Trials / Withdrawn
WithdrawnNCT01655186
A Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Effects of Bardoxolone Methyl on Body Composition in Patients With Stage 4 Chronic Kidney Disease and Type 2 Diabetes Mellitus
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Biogen · Industry
- Sex
- All
- Age
- 30 Years
- Healthy volunteers
- Not accepted
Summary
This multicenter, randomized, double-blind, placebo-controlled Phase 2 safety study will assess the effect of bardoxolone methyl relative to placebo on body weight and fat mass in approximately 60 patients with stage 4 Chronic Kidney Disease (CKD) and Type 2 Diabetes Mellitus (T2DM).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bardoxolone Methyl | |
| DRUG | Placebo |
Timeline
- Start date
- 2012-09-30
- Primary completion
- 2012-10-31
- Completion
- 2012-10-31
- First posted
- 2012-08-01
- Last updated
- 2025-05-29
Source: ClinicalTrials.gov record NCT01655186. Inclusion in this directory is not an endorsement.